Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim D Hewitson

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
BMC Nephrology|July 18, 2020
Vascular calcification in skin and subcutaneous tissue in patients with chronic and end-stage kidney diseaseIrene Ruderman, Tim D Hewitson, Edward R Smith, et al.
The International Journal of Biochemistry & Cell Biology|September 16, 2006
Role of the phosphatidylinositol 3-kinase and mTOR pathways in the regulation of renal fibroblast function and differentiationCatherine E Winbanks, Lauren Grimwood, Anna Gasser, et al.
Journal of Biomedicine & Biotechnology|December 14, 2011
Explanting is an ex vivo model of renal epithelial-mesenchymal transitionCatherine E Winbanks, Ian A Darby, Kristen J Kelynack, et al.
Kidney International|May 20, 2004
Relaxin-1-deficient mice develop an age-related progression of renal fibrosisChrishan S Samuel, Chongxin Zhao, Courtney P Bond, et al.
Hypertension (Dallas, Tex. : 1979)|May 29, 2014
Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart diseaseChrishan S Samuel, Hasangika Bodaragama, Jacqueline Y Chew, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 10, 2004
Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitroRosemary Masterson, Tim D Hewitson, Kristen Kelynack, et al.
Frontiers in Pharmacology|April 12, 2016
The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOateChao Wang, Barbara K Kemp-Harper, Martina Kocan, et al.
Protein and Peptide Letters|January 25, 2013
The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetesSu Ee Wong, Chrishan S Samuel, Darren J Kelly, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|January 7, 2006
Implementation of a pre-dialysis clinical pathway for patients with chronic kidney diseaseJulie E Owen, Rowan J Walker, Laney Edgell, et al.
Journal of Circulating Biomarkers|August 28, 2018
High-intensity physical exercise increases serum <i>α</i>-klotho levels in healthy volunteersSven-Jean Tan, Melissa M Chu, Nigel D Toussaint, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
BMC Nephrology|July 18, 2020
Vascular calcification in skin and subcutaneous tissue in patients with chronic and end-stage kidney diseaseIrene Ruderman, Tim D Hewitson, Edward R Smith, et al.
The International Journal of Biochemistry & Cell Biology|September 16, 2006
Role of the phosphatidylinositol 3-kinase and mTOR pathways in the regulation of renal fibroblast function and differentiationCatherine E Winbanks, Lauren Grimwood, Anna Gasser, et al.
Journal of Biomedicine & Biotechnology|December 14, 2011
Explanting is an ex vivo model of renal epithelial-mesenchymal transitionCatherine E Winbanks, Ian A Darby, Kristen J Kelynack, et al.
Kidney International|May 20, 2004
Relaxin-1-deficient mice develop an age-related progression of renal fibrosisChrishan S Samuel, Chongxin Zhao, Courtney P Bond, et al.
Hypertension (Dallas, Tex. : 1979)|May 29, 2014
Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart diseaseChrishan S Samuel, Hasangika Bodaragama, Jacqueline Y Chew, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 10, 2004
Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitroRosemary Masterson, Tim D Hewitson, Kristen Kelynack, et al.
Frontiers in Pharmacology|April 12, 2016
The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOateChao Wang, Barbara K Kemp-Harper, Martina Kocan, et al.
Protein and Peptide Letters|January 25, 2013
The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetesSu Ee Wong, Chrishan S Samuel, Darren J Kelly, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|January 7, 2006
Implementation of a pre-dialysis clinical pathway for patients with chronic kidney diseaseJulie E Owen, Rowan J Walker, Laney Edgell, et al.
Journal of Circulating Biomarkers|August 28, 2018
High-intensity physical exercise increases serum <i>α</i>-klotho levels in healthy volunteersSven-Jean Tan, Melissa M Chu, Nigel D Toussaint, et al.
Pageof 9